Proportion of patients with hypersensitivity reactions;Proportion of patients with injection-site reactions (ISRs);Severity of hypersensitivity reactions over time;Severity of ISRs;Severity of TEAEs;Time to COVID-19 symptoms resolution;Time-weighted average (TWA) daily change from baseline in viral load (log10 copies/mL);Treatment emergent adverse events (TEAEs)

Proportion of patients with hypersensitivity reactions;Proportion of patients with injection-site reactions (ISRs);Severity of hypersensitivity reactions over time;Severity of ISRs;Severity of TEAEs;Time to COVID-19 symptoms resolution;Time-weighted average (TWA) daily change from baseline in viral load (log10 copies/mL);Treatment emergent adverse events (TEAEs)